Status:
COMPLETED
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of...
Eligibility Criteria
Inclusion
- In patients with malignant tumor who have been treated with albumin-bound paclitaxel for the treatment.
Exclusion
- No
Key Trial Info
Start Date :
May 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04060290
Start Date
May 12 2020
End Date
February 1 2024
Last Update
February 28 2024
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Cancer Hospital
Hefei, Anhui, China
2
Maanshan People's Hospital
Maanshan, Anhui, China
3
Hainan General Hospital
Haikou, Hainan, China
4
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China